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Dendritic cellRapid advances in immune system knowledge have led to the exploration of immunologic approaches for
eliminating tumor cells. Human telomerase reverse transcriptase (hTERT) is considered to be an ideal universal
target for novel immunotherapies against cancers. Thus far, studies of effective antitumor immunotherapies have
focused on the quantity and quality of the effector function of the CD8 compartment. However, increasing
evidence has demonstrated that CD4+ T cells play important roles in generating and maintaining antitumor
immune responses in animalmodels. The aimof thisworkwas to verifywhether diepitopemultiple antigen pep-
tides (MAPs) thatwere composed of the cytotoxic T lymphocyte (CTL) epitope of hTERT and the T-helper epitope
of hTERT could improve upon the immunogenicity of a monoepitopeMAP of hTERT. Dendritic cells (DCs) pulsed
with diepitopeMAPs composed of the CTL epitope hTERT-540 and the T-helper epitope hTERT-766were used to
evaluate immune responses against various tumor cells. A standard in vitro 4-h 51Cr-release assaywas employed
in this study. The results demonstrated that CTLs activated by the diepitopeMAP that consisted of hTERT-540 and
hTERT-766 could cause 8.56% more lysis than CTLs activated by the monoepitope MAP containing hTERT-540.
Moreover, the activated CTLs could kill neither hTERT-negative tumor cells, such as U2OS cells, nor HLA-A2
negative cells, such as HepG2 cells. Our results indicate that diepitope MAPs that are generated from hTERT
can be exploited for cancer immunotherapy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
In contrast to traditional chemotherapy, which uses agents that
produce widespread cytotoxicity to kill tumor cells, immunotherapy
focuses on empowering the immune system to overcome a tumor.
Recent rapid advances in immune system knowledge have led to the
exploration of immunologic approaches for the elimination of tumor
cells. However, the development of a therapeutic antitumor vaccine re-
mains a great challenge that has not yet been surmounted. Therapeutic
vaccines rely on some other material. This material may include either
pulsed effector cells, such as dendritic cells (DCs), or tumor-associatedtarget ratio; ELISPOT, enzyme
RT, human telomerase reverse
eripheral blood mononuclear
o), shimingyang@yahoo.com
this study.
.V. Open access under CC BY-NC-ND lantigens (TAAs) and their derivatives, such as peptides [1] or nucleic
acids.
Human telomerase reverse transcriptase (hTERT), a critical enzyme
involved in telomerase, is associated with tumor growth, development
and invasion [2]. In fact, hTERT is highly expressed in over 85% of human
tumors and virtually all types of cancer but is inactive in most normal so-
matic cells [3]. These observations suggest that hTERT could potentially be
an ideal candidate for a universal TAA. Our previous study indicated that
an hTERT recombinant adenovirus vaccine and a peptide-nucleotide dual
vaccine could induce hTERT-speciﬁc cytotoxic T lymphocytes (CTLs) both
in vitro and in vivo [4,5].
Multiple hTERT-derived MHC-expressed epitopes have been identi-
ﬁed. [6] Compared with the HLA-DR-presented peptides, the HLA-A2-
presented peptides are better characterized; moreover, the HLA-A2-
presented peptides have successfully generated reactive lymphocytes
both in vitro and in vivo.[7–9] The existing studies of effective antitumor
immunotherapies have largely focused on the quantity and quality of the
effector function of CD8+ T cells. This emphasis is understandable, given
that CTLs are considered to be the chief mediators of tumor immuno-
surveillance. However, increasing evidence has demonstrated that
CD4+ T cells play important roles in generating and maintaining anti-
tumor immune responses [10–12]. In another of our studies,we enumer-
ated the hTERT-speciﬁc CD8+ T cells by ELISPOT and surprisingly found
that the number of IFN-r-producing effectors was signiﬁcantly reducedicense.
Fig. 1. Analogue structure of Diepitope MAP and monoepitope of hTERT-540: A
diepitope MAP contained a HLA-DR restricted T helper epitope of hTERT, hTERT-766
(LTDLQPYMRQFVAHL), at the C-terminus of the HLA-A2 restricted CTL epitope,
hTERT-540, with a linker of “–Gly–Gly–Gly–”; B monoepitope MAP consisting of four
copies of HLA-A2 restricted CTL eitope, hTERT-540.
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with a MAP or with a linear peptide [13,14]. This result demonstrated
that CD4+ T cells could play an essential role in the priming of naive
CD8 responses.
Although peptide vaccines are easily synthesized and safe to use,
their small molecular weight, single structure, high degradability and
short half-life cause these vaccines to have only aweak immunogenicity,
and they cannot induce an ideal immune response in vivo [15,16].
Branched peptides, such as multiple antigen peptides (MAPs), were
invented in 1988 by Tam; these peptides have been examined for their
potential uses as diagnostic reagents for serodiagnoses; vaccines against
bacteria, viruses and parasites; and inhibitors of pathogenic infections
[17]. MAPs have been considered to be potential new strategies for
antitumor immunotherapy. MAPs provide many beneﬁts as immuno-
gens, such as the simplicity of their design and synthesis, their versatilityFig. 2. Expression of hTERT and HLA-A2 in target cells. A. Expression of hTERT mRNA in
KATO-III; 4, SW480; 5, MCF-7; 6, HepG2; B. HLA-A2 expression in various target cells.for investigating various immune responses, their reliability for generat-
ing site-speciﬁc antibodies and their capability for generating site-
speciﬁc antibodies in a laboratory context [18]. Our previous study
demonstrated that stronger anti-tumor immune responses could be
triggered by MAPs based on HLA-A2-restricted CTL epitopes of hTERT
than by their corresponding linear peptides [13].
Based on the above analyses, it may be necessary to engage both
CD8+ and CD4+ T cells to achieve more effective antitumor immu-
notherapy. In this study, we took advantage of the simplicity of
the design and synthesis of MAPs to create one diepitope MAP that
contained an HLA-DR-restricted T-helper epitope of hTERT-L766 at
the C-terminus of hTERT-540, the HLA-A2-restricted CTL epitope;
one monoepitope MAP that consisted of four copies of hTERT-540.
The immune responses triggered by these molecules against vari-
ous tumor cells were evaluated using a standard 4-h 51Cr-release
assay.2. Materials and methods
2.1. Cell lines
The human colon carcinoma cell line SW480 (hTERT+, HLA-A2+),
the human gastric carcinoma cell line KATO-III (hTERT+, HLA-A2+),
the human osteogenic sarcoma cell line U2OS (hTERT-, HLA-A2+),
the human breast cancer cell line MCF-7 (hTERT+, HLA-A2+) and
the human hepatoma carcinoma cell line HepG2 (hTERT+, HLA-A2-)
were purchased from the American Type Culture Collection (ATCC,
USA) and stored in our laboratory. HepG2/HLA-A2 cells (hTERT+,
HLA-A2+) that were transfected with a plasmid encoding the chime-
ric heavy chain of the MHC-I molecule and U2OS/hTERT cells
(hTERT+, HLA-A2+) that were transfected with a plasmid vector
containing the full-length cDNA of hTERT were constructed and
stored in our laboratory [19]. The KATO-III, HepG2, MCF-7, U2OS
and SW480 cells were cultured in RPMI-1640 medium containing
10% fetal bovine serum (FBS). All of the cells were kept at 37 °C in a
humidiﬁed atmosphere that contained 5% CO2.target cells by RT-PCR. GAPDH served as reference gene. 1, U2OS; 2, U2OS/hTERT; 3,
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The recombinant adenovirus vector encoding hTERTwas constructed,
ampliﬁed and identiﬁed using previously described methods [5].
2.3. Synthetic peptides
OnediepitopeMAP that containedhTERT-766 (LTDLQPYMRQFVAHL),
an HLA-DR-restricted T-helper epitope of hTERT, at the C-terminus of
hTERT-540 (ILAKFLHWL), the HLA-A2 restricted CTL epitope, with a
linker of “–Gly–Gly–Gly–” between these two epitopes (Fig. 1A); one
monoepitope MAP consisting of four copies of hTERT-540, (Fig. 1B); and
their corresponding linear peptides were synthesized by the Shanghai
Qiangyao Biotechnology Ltd. Co. (Shanghai, China). One nonapeptide
from the HIV sequence [HIVpol (476–484) (ILLEPVHGV)], which was
used as a negative control, was synthesized by the Beijing Scilight
Biotechnology Ltd. Co. (Beijing, China). Themolecularweights of the pep-
tides that were used in this study were validated by mass spectrometry
(API2000, phycoerythrin (PE)). The lyophilized peptides were dissolved
in dimethyl sulfoxide (DMSO; Sigma) and stored at−20 °C.
2.4. The generation of DCs from human peripheral bloodmononuclear cells
The DCs from peripheral blood mononuclear cells (PBMCs) were
generated using previously published procedures [20]. In brief, PBMCs
were isolated fromHLA-A2+donors by Ficoll-Hypaque density gradient
centrifugation. The cells (106/ml) were allowed to adhere for 2 h in cul-
ture ﬂasks at 37 °C in RPMI-1640 with 10% FBS. The non-adherent cells
were then collected and frozen in freezing medium (60% RPMI-1640,
30% FBS, and 10% DMSO) for later use in CTL assays. Adherent cells
were cultured in 6 ml of RPMI-1640 containing 10% FBS, 800 U/ml of
recombinant human granulocyte-macrophage colony-stimulating fac-
tor (rhGM-CSF, R&D System, Inc., USA) and 1200 U/ml of recombinant
human interleukin-4 (rhIL-4, R&D System, Inc., USA). On days 3, 5,
and 7 of the cell culture process, half of the culture medium was
refreshed without discarding any cells, and fresh cytokine-containingFig. 3. Phenotype of mature DCmedium (medium containing rhGM-CSF and rhIL-4) was added. On
day 8 of the cell culture process, 1000 U/ml of tumor necrosis factor α
(TNF-α, R&D System, Inc., USA) was added to the cell growth medium.
Onday 9, the non-adherent cells thatwere obtained from these cultures
were considered to be mature human-PBMC-derived DCs.
The phenotypes of themature DCs thatwere generated from PBMCs
were detected by ﬂow cytometry, using PE-conjugated anti-human
CD86, ﬂuorescein isothiocyanate (FITC)-conjugated anti-human CD83
and FITC-conjugated anti-human CD1α.
2.5. Flow cytometry
The phenotypes of mature DCs were determined by ﬂow cytometry
in accordance with previously published procedures [21]. In brief, the
DCs (5 × 105/ml) that were generated from PBMCs were immuno-
stained with FITC-conjugated mouse anti-human CD1a and CD83 and
PE-conjugated anti-human CD86 antibodies (eBioscience, USA) for 2 h
at 4 °C. The corresponding FITC immunoglobulin G (IgG) isotype con-
trol antibodies (eBioscience, USA) were used. The immunostained
cells were washed once with FACS buffer, resuspended, and analyzed
with a FACScan (Becton–Dickinson, USA).
HLA-A2 analysis of target cell lines (KATO-III, SW480, MCF-7, U2OS,
HepG2, HepG2/HLA-A2) was also performed by ﬂow cytometry as pre-
viously described [22]. In brief, Anti-HLA-A2 mAbs BB7.2 (culture su-
pernatant, which was stored in our laboratory) was used as primary
reagent. FITC-conjugated GAM-IgG-F(ab')z (JinQiao Biotechnology Ltd.
Co, Bejing, China) was used for the second incubation.
2.6. The generation of hTERT-speciﬁc effector cells in vitro
Mature human PBMC-derived DCs (1 × 105/ml) were pulsed for
4 h with 30 uM/ml of either diepitope MAPs, monoepitope MAPs or
a linear peptide corresponding to one of these MAPs. As a positive
control, other DCs were pulsed with a recombinant adenovirus-
hTERT vector for 24 h. The DCs were irradiated with 20 Gy to prevent
outgrowth. Subsequently, the non-adherent autologous peripherals generated from PBMCs.
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800 U/ml of recombinant IL-2 was added. On day 7, and weekly there-
after, the autologous peripheral blood lymphocytes were restimulated
with peptide-pulsed or adenovector-pulsed irradiated DCs.
2.7. Cytotoxicity assay
To evaluate the levels of CTL activity, a standard 4-h 51Cr-release
assay was used. The target cells, namely, the SW480, KATO-III,
U2OS, U2OS/hTERT, HepG2, HepG2/HLA-A2 and MCF-7 cells, were
labeled with 100 μCi 51Cr in 1 ml of RPMI-1640 containing 10% FBS for
2 h at 37 °C in 5% CO2. The labeled target cells were washed three
times with RPMI-1640 medium without serum. The target cells were
then plated in triplicate at a ﬁnal concentration of 1 × 104 cells/well
in 96-well V-bottom microtiter plates. The 51Cr-labeled target cells
(100 μl) were mixed with effector cells at effector-to-target ratios (E: T)
of 10:1, 20:1, 40:1, and 80:1. After an incubation of the resulting cell mix-
tures for 4 h at 37 °C in 5% CO2, the release of the 51Cr labelwasmeasured
by collecting 100 μl of the supernatant and quantitating this supernatant
in an automated gamma counter (Beijing Nuclear Instrument Factory,
China). The percentage of speciﬁc lysis was calculated to be the percent-
age of speciﬁc 51Cr release that was determined using the following
formula:
Speciﬁc Lysis = (experimental release − spontaneous release)/
(maximal release − spontaneous release) × 100%
2.8. Statistics
The statistical analyses were performed using Student's t-tests.
Differences with P values that were less than 0.05 were considered to
be statistically signiﬁcant. All of the statistical analyses were conducted
using the SPSS 17.0 software package.Fig. 4. Speciﬁc lysis of tumor cells by CTLs activated by monoepitope MAPs of hTERT-54
x-axis, and the y-axis shows percent speciﬁc lysis. CTLs induced by one nonapeptide from
adenovector encoding full length hTERT, monoepitope MAP vaccines of hTERT-540 or th
MCF-7, U2OS, U2OS/hTERT, HepG2, HepG2/HLA-A2. Results are given as the mean ± SD. *3. Results
3.1. hTERT and HLA-A2 expression in various target cells
In this study, we used RT-PCR to test the hTERT mRNA expression
in all of the target cell lines. The results demonstrated that hTERT
mRNA was detected in KATO-III, SW480, MCF-7 and HepG2 cells.
In addition, hTERT mRNA expression was not detected in U2OS cells
but was detected in U2OS/hTERT cells, which had been transfected
with a plasmid vector containing the full-length cDNA of hTERT
(Fig. 2A).
We also tested for HLA-A2 expression in target cells by ﬂow cytom-
etry. The results revealed that the expression of HLA-A2 in KATO-III,
SW480, MCF-7 and U2OS cells was 98.87%, 100.00%, 98.97%, and
99.67%, respectively. However, the HLA-A2 expression in HepG2 cells
was only 9.6%. After transfection with a plasmid encoding HLA-A2, the
HLA-A2 expression of HepG2/HLA-A2 cells increased to 89.2% (Fig. 2B)
3.2. The identiﬁcation of mature DCs by ﬂow cytometry
The phenotype of the mature DCs generated from PBMCs was
identiﬁed by ﬂow cytometry. The results demonstrated that the expres-
sion rates of CD86, CD83, CD1α, and HLA-A2 in the DCs that
were generated from PBMCs were 98.67%, 73.29%, 66.68% and 96.84%,
respectively; these ﬁndings indicated that these DCs were mature and
demonstrated maximal antigen-presentation capabilities (Fig. 3).
3.3. The hTERT-speciﬁc MAPs induce stronger anti-tumor responses than
their corresponding linear peptides
To analyze immune responses against tumor cell lines in vitro,
mature DCs were pulsed with monoepitope MAPs of hTERT-540 and0 and their corresponding linear peptide. Effector-to-target ratios are shown on the
the HIV sequence served as a negative peptide (NP). Speciﬁc lysis of CTLs induced by
eir corresponding linear peptide pulsed DCs from PBMCs against KATO-III, SW480,
Statistically signiﬁcant values at P b 0.05.
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adenovirus-hTERT vector served as the positive controls for this study,
whereas DCs pulsed with HIV polypeptides served as the negative
controls of the study. The autologous peripheral blood lymphocytes
were stimulated three times by the peptide-pulsed DCs. We then used
a standard 4-h 51Cr-release assay to analyze the ability of these
lymphocytes to lyse various human tumor cells, namely, KATO-III,
SW480 and MCF-7, which express both hTERT and HLA-A2. The results
demonstrated that compared with the linear peptide of hTERT-540, the
monoepitope MAP of hTERT-540 could cause 26.5% (P = 0.00) more
lysis at the highest E/T ratio (80:1) that was examined, although the
lysis rate demonstrated by this monoepitope MAP was lower than the
lysis rate that was caused by the adenovirus-hTERT vector (Fig. 4A)
(P = 0.00). The activated CTLs could kill neither hTERT-negative
tumor cells, such as U2OS cells (Fig. 4B), nor HLA-A2 negative cells,
such as HepG2 cells (Fig. 4C).
3.4. The hTERT-speciﬁc CD8+ T cell responses require CD4+ T cell help
In our previous study, through our enumeration of the hTERT-
speciﬁc CD8+ T cells by ELISPOT, we surprisingly found that the num-
ber of IFN-r-producing effectors was signiﬁcantly reduced in CD4-
depleted mice, regardless of whether these mice were vaccinated with
MAPs or linear peptides. This result demonstrated that CD4+ T cells
played an essential role in the priming of naive CD8 responses by
maintaining CD8+ T-cell quantities. Therefore, in this study, we
designed a diepitope MAP and its corresponding linear peptide. These
peptides were composed of CTL epitope hTERT-540 and T-helper
epitope hTERT-766 and had a “–Gly–Gly–Gly–” linker joining these
epitopes. A standard 4-h 51Cr-release assay was used to evaluate
the resulting immune responses against various tumor cell lines. TheFig. 5. Speciﬁc lysis of tumor cells by CTLs activated by linear peptide consisting of hTER
shown on the x-axis, and the y-axis shows percent speciﬁc lysis. CTLs induced by one nona
induced by adenovector encoding full length hTERT, linear peptide consisting of hTERT-5
KATO-III, SW480, MCF-7, U2OS, U2OS/hTERT, HepG2, HepG2/HLA-A2. Results are given asresults demonstrated that at the highest E/T ratio (80:1), the linear
peptide consisting of hTERT-540 and hTERT-766 could cause 6.12%
(P = 0.03) more lysis compared with the linear peptide of hTERT-540
(Fig. 5A); in addition, at this E/T ratio, the diepitope MAP consisting of
hTERT-540 and hTERT-766 could cause 8.56% (P = 0.02) more lysis
than the monoepitope MAP of hTERT-540 (Fig. 6A). However, the acti-
vated CTLs could neither kill hTERT-negative tumor cells, such as U2OS
cells, nor kill HLA-A2 negative cells, such as HepG2 cells (Fig. 5B, Fig. 5C,
Fig. 6B, Fig. 6C).
3.5. The hTERT-speciﬁc effectors do not lyse autologous lymphocytes or DCs
It has been reported that hTERT is abundantly present in most
human tumor cells; however, hTERT is also expressed in certain
normal somatic cells, such as stem-cells, activated lymphocytes, basal
keratinocytes andDCs. Therefore, in the present study, we used standard
4-h 51Cr-release assay to investigate whether hTERT-speciﬁc effectors
lyse autologous lymphocytes and DCs. The results of this assay indicated
that the effectors that were primed by either of these peptides or by the
adenovector-pulsed DCs could lyse neither autologous lymphocytes nor
human PBMC-derived DCs in vitro (Fig. 7).
4. Discussion
In our study, we took advantage of the simple aspects of the
design and synthesis of MAPs to explore an hTERT-based active
immunotherapy that used a diepitopeMAP conﬁguration and a DC vec-
tor. We demonstrated that stronger immune responses against tumor
cells could be elicited by diepitope MAPs composed of hTERT-540 and
hTERT-766 than by either monoepitope MAPs of hTERT-540 or the
linear peptides that correspond to these MAPs.T-540 and hTERT-766 and linear peptide of hTERT-540. Effector-to-target ratios are
peptide from the HIV sequence served as a negative peptide (NP). Speciﬁc lysis of CTLs
40 and hTERT-766 and linear peptide of hTERT-540 pulsed DCs from PBMCs against
the mean ± SD. * Statistically signiﬁcant values at P b 0.05.
Fig. 6. Speciﬁc lysis of tumor cells by CTLs activated by diepitope MAP consisting of hTERT-540 and hTERT-766 and monoepitope MAP of hTERT-540. Effector-to-target ratios
are shown on the x-axis, and the y-axis shows percent speciﬁc lysis. CTLs induced by one nonapeptide from the HIV sequence served as a negative peptide (NP). Speciﬁc lysis of CTLs
induced by adenovector encoding full length hTERT, diepitope MAP consisting of hTERT-540 and hTERT-766 and monoepitope MAP of hTERT-540 pulsed DCs from PBMCs against
KATO-III, SW480, MCF-7, U2OS, U2OS/hTERT, HepG2, HepG2/HLA-A2. Results are given as the mean ± SD. * Statistically signiﬁcant values at P b 0.05.
449Z.-L. Liao et al. / International Immunopharmacology 16 (2013) 444–450MAPs contain a multibranched lysine core with antigenic peptides.
The MAP system can deliver not only multiple B-cell epitopes but
also T-cell epitopes, and its value has already been established for the
development of vaccines for infectious diseases and tumors [23,24].
Akira et al. previously demonstrated that immunization with a pRL1a
MAP efﬁciently induced CTL generation in vitro and inhibited in vivo
RL♂1 tumor growth. The pRLla MAP enhanced immunogenicity and
generated CTLs against the pRLla peptide [25]. In another study, Seisuke
et al. found that the pRL1a MAP was mostly internalized to antigen-
presenting cells (DCs and P815 cells), which produced pRL1a peptide
epitopes for presentation with H-2 Ld [26]. In this study, we used
TNF-induced mature DCs that were pulsed with a recombinant
adenovirus-hTERT vector or with hTERT-derived peptides, including
MAPs and their corresponding linear peptides, to test the immunoge-
nicity of these peptides. The phenotypes of the mature DCs generated
from PBMCs were identiﬁed by ﬂow cytometry before these DCs were
used to pulse hTERT-derived peptides. We also demonstrated that
stronger CTL responses against tumor cells could be triggered by
MAPs than by their corresponding linear peptides.
It is known that both antigen-speciﬁc CTLs and CD4+ T-helper cells
are needed for eliciting potent antitumor immunity. CD4+ T cells are
important for the tumor-speciﬁc cytotoxicity of CTLs because CD4+ T
cells maintain the quantities of CD8+ T cells and induce memory re-
sponses [27]. To engage both CD8+ and CD4+ T cells for more effective
antitumor immunotherapy, Shi et al. explored the possibilities offered
by linear polypeptides composed of immunodominant CTL, B cell and
T-helper epitopes with short and ﬂexible “–Gly–Gly–Gly–” linkers and
found that these polypeptides could improve the immunogenicity of
CTL epitopes in vivo. This result was consistent with the ﬁndings of
the current study, which indicated that a DC-pulsed linear peptide
consisting of the CTL epitope hTERT-540 and the T-helper epitope
hTERT-766 with a short “–Gly–Gly–Gly–” linker sequence producedgreater in vitro immunogenicity than a linear peptide containing
hTERT-540 alone.
The evolution of the MAP also allows for the incorporation of
multiple copies of two ormore epitopes in a deﬁned anddeliberateman-
ner. Diepitope MAPs have been used to enhance the immunogenicity of
B cell epitopes. Several studies have indicated that diepitope MAP con-
structs incorporating B cell and T-helper epitopes from different sources
induce strong antibody responses against monoepitopeMAPs consisting
of B cell epitopes [28]. In the current study, we took advantage of the
simplicity of designing and synthesizingMAPs to examine one diepitope
MAP that contained a T-helper epitope of hTERT, hTERT-766, that
was linked by “–Gly–Gly–Gly–” to the C-terminus of the CTL epitope
hTERT-540. The study results demonstrated that a stronger immune
response against tumor cells could be elicited by this diepitope MAP
than by the monoepitope MAP that only contained copies of the
hTERT-540 epitope. The main drawback with this method is that new
immunodominant epitopes may be formed that do not preserve the
intended design of the desired MAP. In this study, on each branching
unit of the diepitope MAP, the hTERT-540 and hTERT-766 sequences
were linked by “–Gly–Gly–Gly–”, thereby decreasing the possibility of
neo-epitope formation and increasing the response to the desired
epitopes. However, the mechanism underlying the effect of the hTERT
epitopes that are generated from hTERT MAPs remains unknown. This
question must be addressed in future studies.
In the development of cancer vaccines, we must remain cognizant of
safety considerations. Although hTERT is abundantly present in most
human tumor cells, it is also expressed in certain normal cells and tissues,
such as the stem-cell precursors of the bonemarrow, the spermatogonia
in the testis, activated lymphocytes and basal keratinocytes. In this study,
we used a 4-h 51Cr-release assay to investigate the ability of effectors to
lyse autologous lymphocytes and DCs and found that hTERT-derived
MAPs were unable to lyse autologous lymphocytes and DCs in vitro.
Fig. 7. The effect of hTERT-speciﬁc CTLs on immunologically activated lymphocytes.
Effector-to-target ratios are shownon the x-axis,whereas the y-axis shows percent speciﬁc
lysis. CTLs induced using one nonapeptide from the HIV sequence [HIVpol (476–484)
(ILLEPVHGV)] served as a negative peptide (NP). Speciﬁc lysis of CTLs generated from
adenovector encoding full length hTERT, diepitope MAPs monoepitope MAPs or their
corresponding linear peptide against autologous lymphocytes and DCs in vitro. Results
are given as the mean ± SD.
450 Z.-L. Liao et al. / International Immunopharmacology 16 (2013) 444–450In conclusion, we demonstrated that greater in vitro immunoge-
nicity could be generated by DCs that were pulsed with diepitope
MAPs containing the CTL epitope hTERT-540 and the T-helper epitope
hTERT-766 than by MAPs containing hTERT-540 epitopes alone.
The diepitope MAP vaccine format, either as a single agent or in com-
bination with other approaches, may offer great promise for cancer
treatments.
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